婴儿FIP1L1-RARA融合相关髓系肿瘤的成功治疗与整合基因组分析
本文报道一名9月龄男婴,表现为FIP1L1-RARA融合相关的骨髓增生异常/骨髓增殖性肿瘤样重叠综合征,兼具急性早幼粒细胞白血病和幼年型粒单核细胞白血病特征。采用化疗、分化剂和异基因造血干细胞移植(allo-HCT)联合治疗,移植后20个月持续缓解。建议对FIP1L1-RARA融合相关髓系肿瘤考虑化疗、分化治疗和allo-HCT联合策略。
要点
- FIP1L1-RARA融合相关肿瘤罕见且侵袭性强,此前仅报道3例。
- 婴儿病例采用化疗、分化剂和allo-HCT联合治疗,移植后20个月缓解。
- 建议对此类肿瘤考虑化疗、分化治疗和allo-HCT联合方案。
核心结论
- FIP1L1-RARA融合相关髓系肿瘤可采用化疗、分化治疗和allo-HCT联合治疗,本例获得长期缓解。
研究设计与样本
- 个案报道:一名9月龄男婴,诊断为FIP1L1-RARA融合相关的MDS/MPN样重叠综合征。
主要发现
- 患者接受化疗、分化剂和allo-HCT联合治疗,移植后20个月保持缓解。
- 该病例为文献中第二例儿童FIP1L1-RARA融合相关肿瘤,也是唯一长期预后良好的病例。
临床怎么用
- 对FIP1L1-RARA融合相关髓系肿瘤,可考虑化疗、分化治疗和allo-HCT联合策略。
局限性
- 仅为单个病例报道,既往文献仅3例,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FIP1L1-RARA-a ssociated neoplasm is a very rare and aggressive disease, with only 3 previously reported cases in the literature. Here, we describe a 9-month-old boy who presented with a FIP1L1-RARA fusion-associated myelodysplastic/myeloproliferative neoplasm-like overlap syndrome, with similarities and distinct features to both acute promyelocytic leukemia and juvenile myelomonocytic leukemia. Using a combined approach of chemotherapy, differentiating agents, and allogeneic hematopoietic stem cell transplant (allo-HCT), this patient remains in remission 20 months after allo-HCT. To our knowledge, this is only the second published pediatric case involving this condition and the only case with a favorable long-term outcome. Given the aggressive disease described in the previously published case report, as well as the successful treatment course described, the combinatorial use of chemotherapy, differentiation therapy, and allo-HCT for treatment of FIP1L1-RARA fusion-associated myeloid neoplasms should be considered.
引用
- Miltiadous O, Petrova-Drus K, Kaicker S, et al. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. Blood Adv. 2022. PMID: 34551074. doi:10.1182/bloodadvances.2021004966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。